Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Allows Claims in Alnylam RNAi Patent Application

Premium

Alnylam Pharmaceuticals said this week that the US Patent and Trademark Office has allowed a patent application covering compositions and methods for siRNAs.

The application, No. 20070275465, is entitled, "Double-Stranded Ribonucleic Acid with Increased Effectiveness in an Organism." According to Alnylam, claims in the application include a dsRNA of any length having effectiveness in inhibiting a target gene via RNAi; overhang or blunt-end design features; and a 19 to 28 nucleotide region of the antisense strand that is complementary to a target gene.

The company acquired the intellectual property through its purchase of Germany's Ribopharma in 2003.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.